case_images: PMC8186120_01
case_images: Clinical aspects of three diabetic cats with hypersomatotropism: (a) cat 1, (b) cat 2 and (c) cat 3
case_images: 10.1177_20551169211018991-fig1.jpg
case_images: PMC8186120_01_10.1177_20551169211018991-fig1.jpg
case_images: fig1-20551169211018991
case_images: BCS of 5/5 in cat 2, and mild broad facial features and mild widening of interdental spaces in cat 3 (Table 1; Figure 1). Blood work and urinalysis results were normal, except for the presence of glycosuria and elevated serum fructosamine concentrations observed in all three cats (Table 2; Figure 2), hyperproteinemia (9.2 g/dl; reference interval [RI] 5-7) and hypercholesterolemia (8.5 mmol/l; RI 2.5-3.7) observed in cat 1.
case_images: Serum fructosamine concentrations before and during treatment with cabergoline in three diabetic cats with hypersomatotropism. Between the second and third months of cabergoline treatment, diabetic remission was achieved in these cats
case_images: 10.1177_20551169211018991-fig2.jpg
case_images: PMC8186120_01_10.1177_20551169211018991-fig2.jpg
case_images: fig2-20551169211018991
case_images: BCS of 5/5 in cat 2, and mild broad facial features and mild widening of interdental spaces in cat 3 (Table 1; Figure 1). Blood work and urinalysis results were normal, except for the presence of glycosuria and elevated serum fructosamine concentrations observed in all three cats (Table 2; Figure 2), hyperproteinemia (9.2 g/dl; reference interval [RI] 5-7) and hypercholesterolemia (8.5 mmol/l; RI 2.5-3.7) observed in cat 1. Between the second and third months of cabergoline treatment, insulin administration was no longer necessary in any of the cats (Figures 2 and 4). Clinical signs of DM had completely disappeared and serum fructosamine concentrations normalized in the third month (cat 1: 340 mumol/l; cat 2: 306 mumol/l; cat 3: 304 mumol/l [RI 200-360]; Figure 2).
case_images: T1-weighted MRI of the sellar region post-gadolinium. Enlargement of the pituitary gland was observed on the MRI of this cat (cat 3): 5.7 mm width x 4.5 mm height. (a) Cross section, pituitary height: brain area ratio = 0.32; (b) sagittal section
case_images: 10.1177_20551169211018991-fig3.jpg
case_images: PMC8186120_01_10.1177_20551169211018991-fig3.jpg
case_images: fig3-20551169211018991
case_images: IGF-1 concentrations were >1500 ng/ml in cat 1 and 1200 ng/ml in cat 2, with values >1000 ng/ml considered indicative of hypersomatotropism. In cat 3, serum IGF-1 concentration was 947 ng/ml; in this case, MRI confirmed enlargement of the pituitary gland (5.7 mm width x 4.5 mm height [normal in mesocephalic cats: up to 4.7 +- 0.31 mm width and up to 3.1 +- 0.25 mm height according to Haussler et al  ]) (Figure 3).
case_images: Home-generated serial blood glucose curves before and during cabergoline treatment (cat 1). All curves started in the morning and finished at evening.. Pre = before treatment with cabergoline; mo = month
case_images: 10.1177_20551169211018991-fig4.jpg
case_images: PMC8186120_01_10.1177_20551169211018991-fig4.jpg
case_images: fig4-20551169211018991
case_images: Additionally, each blood glucose curve showed the necessity to reduce the insulin dose progressively (Figure 4). Between the second and third months of cabergoline treatment, insulin administration was no longer necessary in any of the cats (Figures 2 and 4).